PALI Palisade Bio Inc

Price (delayed)

$1.01

Market cap

$181.07M

P/E Ratio

1.11

Dividend/share

N/A

EPS

$0.91

Enterprise value

$67.4M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: 76
Relative Profitability: Rel. Profitability: 20

Palisade Bio is a late-stage biopharmaceutical company advancing oral therapies that aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s lead clinical ...

Highlights
The EPS has soared by 143% YoY and by 52% from the previous quarter
Palisade Bio's debt has shrunk by 100% YoY
The net income has contracted by 37% from the previous quarter
The quick ratio has declined by 19% since the previous quarter

Key stats

What are the main financial stats of PALI

PALI stock price

How has the Palisade Bio stock price performed over time
Intraday
-1.94%
1 week
-10.62%
1 month
-28.37%
1 year
-51.21%
YTD
-57.02%
QTD
-25.19%

Financial performance

How have Palisade Bio's revenue and profit performed over time
Revenue
$500,000
Gross profit
$500,000
Operating income
-$48.13M
Net income
-$43.7M
Gross margin
100%
Net margin
-8,739.2%
Palisade Bio's net margin has decreased by 37% QoQ
The net income has contracted by 37% from the previous quarter
Palisade Bio's operating margin has decreased by 36% from the previous quarter
The operating income has contracted by 36% from the previous quarter

Price vs fundamentals

How does PALI's price correlate with its fundamentals

Growth

What is Palisade Bio's growth rate over time

Valuation

What is Palisade Bio stock price valuation
P/E
1.11
P/B
1.57
P/S
428.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
134.81
The EPS has soared by 143% YoY and by 52% from the previous quarter
PALI's P/B is 36% below its last 4 quarters average of 2.5 but 14% above its 5-year quarterly average of 1.4
The equity has decreased by 8% from the previous quarter

Efficiency

How efficient is Palisade Bio business performance
PALI's ROE has soared by 85% YoY but it is down by 6% from the previous quarter
Palisade Bio's ROA has soared by 75% YoY but it has decreased by 7% from the previous quarter
The ROS has decreased by 37% from the previous quarter

Dividends

What is PALI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PALI.

Financial health

How did Palisade Bio financials performed over time
Palisade Bio's total liabilities has soared by 62% YoY and by 10% from the previous quarter
The quick ratio has declined by 19% since the previous quarter
Palisade Bio's debt is 100% lower than its equity
PALI's debt to equity has dropped by 100% year-on-year
Palisade Bio's debt has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.